Screener / SEC EDGAR /CIK 0001157601 /10-K filed Feb 19, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Madrigal Pharmaceuticals, Inc. MDGL

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 19, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-276.4% to -31.3% (+245.1 pts)

“Research and development expenses increased by $151.8 million in 2025 primarily due to business development transactions, including $120.0 million upfront expense under the CSPC License Agreement and $50.0 million under the Pfizer License Agreement, partially offset by a reduction in expenses related to clinical trials.”

Read it in the 10-K

“Selling, general and administrative expenses increased by $378.8 million in 2025 primarily due to an increase in commercial activities for Rezdiffra, including a corresponding increase in headcount to support our commercialization efforts.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+432.1%

The MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.